Navigation Links
Elesclomol Study Shows Significant Improvement in Progression-Free Survival for Chemotherapy-Naive Patients With Metastatic Melanoma
Date:5/20/2008

tructures. All Synta drug candidates were invented by Synta scientists using our compound library and drug discovery capabilities. Synta has a partnership with GlaxoSmithKline for the joint development and commercialization of its lead investigational drug candidate, elesclomol, which is in a global, pivotal Phase III clinical trial for the treatment of metastatic melanoma. For more information, please visit http://www.syntapharma.com.

GlaxoSmithKline Cautionary Statement Regarding Forward-Looking Statements

Under the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995, GSK cautions investors that any forward-looking statements or projections made by GSK, including those made in this announcement, are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Factors that may affect GSK's operations are described under 'Risk Factors' in the 'Business Review' in the company's Annual Report on Form 20-F for 2007.

Synta Pharmaceuticals Corp. Safe Harbor Statement

This media release may contain forward-looking statements about Synta Pharmaceuticals Corp. Such forward-looking statements can be identified by the use of forward-looking terminology such as "will", "would", "should", "expects", "anticipates", "intends", "plans", "believes", "may", "estimates", "predicts", "projects", or similar expressions intended to identify forward-looking statements. Such statements, including statements relating to the timing and progress of our clinical and preclinical programs, reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such forward-looking statements, including those described in "Risk Factors" of our Form 10-K for the year ended December 31, 2007 as filed
'/>"/>

SOURCE GlaxoSmithKline; Synta Pharmaceuticals Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Palatin Technologies Initiates Phase 2 Hypertension Clinical Study With PL-3994
2. Fuisz Tobacco Announces Clinical Study Results for Fuisz Tobacco Sheet Strip; Super Enhanced Bioavailability of Nicotine From Its Tobacco Sheet Strip Supports Efficacy of Low Dose Tobacco Product
3. Delcath Updates Phase III Patient Enrollment as Pivotal Trial Accelerates, Durable Tumor Responses In Phase II Study Also Cited
4. Pivotal Study Shows Physician/Nurse Teams Using SEDASYS(TM) System Reduced Risk of Over Sedation With Propofol
5. Amikacin Inhale Shows Promising Results in Phase II Study
6. Ikaria Completes Dosing of Phase 1a Clinical Study for IK-1001 (Sodium Sulfide) for Injection
7. Infant Vaccines Produce Autism Symptoms in New Primate Study by University of Pittsburgh Scientists
8. ADVENTRX Announces ANX-530 Safety Data From Registrational Bioequivalence Clinical Study
9. Nexavar Significantly Improves Overall Survival by 47 Percent in Asia-Pacific Liver Cancer Study
10. Landmark ATHENA Study Findings With Multaq(R) (dronedarone) Shows 24% Reduction In Cardiovascular Hospitalization or Death in Patients With Atrial Fibrillation
11. Quigley Announces Successful Poultry Study of Chickens With Infectious Bronchitis; Plans to Approach the Poultry Industry for Potential Commercialization
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/26/2014)... NEW YORK and LONDON ... distributor of market intelligence, MarketResearch.com is pleased to announce ... Research and Consultancy focusing on the active pharmaceutical ingredient ... Research visit: http://www.marketresearch.com/land/publisher.asp?vendorid=4023&progid=86891 . In ... Market – Forecast to 2020 , ...
(Date:11/26/2014)... , Nov. 25, 2014  goBalto, Inc., the ... been recognized as a winner of Red Herring,s ... Global Top 100 North America award in 2013, marking ... technology landscape. Red Herring,s Top 100 Global ... promising new companies and entrepreneurs. Red Herring editors were ...
(Date:11/26/2014)... , Nov. 25, 2014 Nanomix ... on the development of mobile diagnostic tests ... in hospital and pre-hospital settings, today announced ... 13485:2003 certification.  The certification was awarded by ... the world,s leading certification bodies. ...
Breaking Medicine Technology:MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 2MarketResearch.com: Active Pharmaceutical Ingredient Market to Reach $175 Billion by 2020 Says IQ4I Report 3goBalto Selected as a 2014 Red Herring Top 100 Global Company 2goBalto Selected as a 2014 Red Herring Top 100 Global Company 3Nanomix Receives ISO 13485:2003 Certification 2
... DIEGO, Oct. 26 The ... Circle at their Annual Scientific Meeting, becoming the first medical association ... collaborative community. Meeting attendees, authors and presenters can, for the ... latest breakthroughs in clinical gastroenterology during -- and well after -- ...
... 26 Sequenom, Inc. (Nasdaq: SQNM ), today ... the company,s interim chief financial officer effective November 10, ... officer and chairman of the board, Harry F. Hixson, ... Prior to the effective date of Mr. Maier,s appointment ...
Cached Medicine Technology:American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 2American College of Gastroenterology to Revolutionize Scientific Exchange on Within3 3Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 2Sequenom Announces Paul Maier to Become Interim Chief Financial Officer 3
(Date:11/27/2014)... Cambrionix Ltd today announced that it ranked number 10 in ... 50 fastest-growing technology companies in the UK. Rankings are ... Cambrionix Ltd grew 2989 percent during this period. ... Cambridgeshire and East and first in the sector of Electronics. ... of the hard work put in by our team who ...
(Date:11/27/2014)... 27, 2014 Blood-borne pathogens raise the ... precautions and procedures in place to counter this. However, ... of things tainted with menstrual blood are taken as ... simpler, more sanitary way to handle tampons and menstrual ... from Sonora, Calif. , He then created a prototype ...
(Date:11/27/2014)... PA (PRWEB) November 27, 2014 "As ... the embarrassing side effects of urinary incontinence," said an ... it and developed this specialized accessory to prevent leakage ... the Incontinence to absorb urine leakage. This prevents stains ... from potential embarrassment. The pad ensures that the individual ...
(Date:11/27/2014)... By Randy Dotinga ... -- Some people,s brains seem pre-wired to acquire a second ... beyond their mother tongue will likely gain a brain boost, ... connected and integrated after learning," said study co-author Ping Li, ... Pennsylvania State University. But it,s even more interesting, Li said, ...
(Date:11/27/2014)... HealthDay Reporter WEDNESDAY, Nov. ... to be safe and produces an immune system response that ... clinical trial results reported by the U.S. National Institutes of ... for the vaccine paves the way for field-testing it in ... as early as January, said Dr. Anthony Fauci, director of ...
Breaking Medicine News(10 mins):Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 2Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 3Health News:Cambrionix Ltd Ranks Top 10 in the Deloitte UK Technology Fast 50 4Health News:Some People May Be Pre-Wired to Be Bilingual 2Health News:Some People May Be Pre-Wired to Be Bilingual 3Health News:Early Trial Promising for Ebola Vaccine 2Health News:Early Trial Promising for Ebola Vaccine 3
... of prostate cancer is common among older men. Being the ... it is the second leading cause of cancer deaths in ... been a increase in number of detected cases. Most men ... and a prostate-specific antigen (PSA) blood test. In rectal exam ...
... found that women with breast cancer are more likely ... blood. A residue of the fungicide hexachlorobenzene (HCB) were ... that DDT or HCB actually cause breast cancer. The ... for mosquito control in developing countries. DDT, HCB and ...
... a study drinking tea on regular basis help protect ... an increased rate of survival following a heart attack.,Researchers ... group of antioxidants known as,flavonoids, which are plentiful in ... in certain fruits and vegetables, including apples, onions, and ...
... found that evening administration of the central alpha(2)-agonists ... in the morning in hypertensive patients. The study ... to receive once-daily evening administration of guanabenz or ... effects of the two drugs in the morning ...
... Researchers at an American university have found that ... chemical. When one chew broccoli, its cells rupture ... sulphoraphanes. To simulate chewing the researchers crushed raw ... Researchers said that broccoli obtained from common supermarket ...
... question of whether daily moderate exercise could actually prevent ... like jogging, hiking, climbing stairs, racket sports and swimming ... from heart disease. Recommendations in the United States and ... walking, is sufficient for good heart health.// A World ...
Cached Medicine News:
... use. Kit comprises: 1 Miller 0 Premature; 1 Miller ... Ad.; 1 Mac 2 Child; 1 Mac 3 Medium ... Standard, 1 Nylon Carrying Case. The Lite Blade Kit ... take your disposable laryngoscopes anywhere. Each blade and handle ...
... The Flipper® is a unique fiberoptic ... bit of anterior exposure sometimes needed during ... the end of the blade to be ... the handle. This one-handed operation produces a ...
... fiberoptic Naso-Pharyngo-Laryngoscope provides a new standard in ... latest in Fujinon engineering combines high resolution ... a wide 90 degree field of view ... diameter. In addition, the FR-120F offers ...
... CCR Medical's Articulating Tip Laryngoscopes ... in the Industry. The articulating ... by providing an improved view ... and Fiber Optic styles. We ...
Medicine Products: